Immune Checkpoint Inhibitors – Special Topics – Special Topics: Trends and Market Dynamics
Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy, including adjuvant and neoadjuvant settings, and they are increasingly being used in novel combinations with both existing and emerging agents. Combinations of PD-1/PD-L1 checkpoint inhibitors with therapies targeting other immune checkpoints, such as CTLA-4 and LAG-3, feature in approved and emerging regimens. This Special Topics report gives a comprehensive market forecast of current and emerging immune checkpoint inhibitors and their market trends and dynamics in a variety of oncology indications.
Questions answered
- What are the approval timelines and current landscapes for approved immune checkpoint inhibitors, and what combination strategies have been more successful?
- What is the market potential and positioning of emerging immune checkpoint inhibitors?
- What is the commercial potential of current and emerging immune checkpoint inhibitors by brand, indication, combination, and geography, and how will the market evolve over the 2023-2033 forecast period?
Geographies
United States, EU5, Japan
Epidemiology
Drug-treated cases by brand, indication, combination type, and geography (across indications for which immune checkpoint inhibitors are approved, or forecast for approval, in existing Clarivate drug market forecasts)
Forecast
10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2033, segmented by indication (with existing Clarivate drug market forecasts), combination type, and geography
Key drugs covered
Approved agents targeting PD-1, PD-L1, CTLA-4, and LAG-3
Emerging therapies
Phase 3/PR agents expected to gain market authorization through 2033
Product description
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications.
